Prognostic factors for skeletal complications from metastatic bone disease in breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 767-779

  Brown, Janet E ^a,b,f   Cook, Richard J ^c   Lipton, Allan ^d   Costa, Luis ^e   Coleman, Robert E ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF WATERLOO   (Canada)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bisphospho nates; Bone metastases; Breast cancer6; Risk factor+; Skeletal related event; Zoledronic acid

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ASPARTATE AMINOTRANSFERASE; CREATININE; LACTATE DEHYDROGENASE; PAMIDRONIC ACID; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PALLIATIVE THERAPY; CHILD; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; NEWBORN; ORTHOPEDIC SURGERY; PAIN ASSESSMENT; PATHOLOGIC FRACTURE; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; RISK ASSESSMENT; SCHOOL CHILD; SPINAL CORD COMPRESSION; VALIDATION PROCESS; VERTEBRA FRACTURE; BONE TUMOR; BREAST TUMOR; FEMALE; FRACTURE; METASTASIS; MIDDLE AGED; PAIN; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SPINE FRACTURE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PAIN; PAIN MEASUREMENT; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPINAL CORD COMPRESSION; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 79952118684     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0981-1     Document Type: Article

References (27)

1. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176 (Pubitemid 32452017)
2. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(Suppl):1588-1594 (Pubitemid 27444031)
3. Major PP, Cook RJ, Chen BL et al (2005) Survival-Adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2:234-240
4. Delea T, McKiernan J, Brandman J et al (2006) Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 4:341-347 (Pubitemid 44420137)
5. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69
6. Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935 (Pubitemid 46223998)
7. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321
8. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
9. Saad F, Gleason DM, Murray R et al (2004) Long-Term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882 (Pubitemid 38807610)
10. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157 (Pubitemid 46606297)
11. Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-Term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613-2621 (Pubitemid 38715767)
12. Brown JE, Thomson CS, Ellis SP et al (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031-2037 (Pubitemid 38030899)
13. Lipton A, Demers L, Curley E et al (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34:2021-2026 (Pubitemid 28546935)
14. Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193-201 (Pubitemid 351976401)
15. Patel B, DeGroot H (2001) Evaluation of the risk of pathologic fractures secondary to metastatic bone disease. Orthopedics 24:612-617 quiz 618-619
16. Major PP, Cook RJ, Lipton A et al (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272
17. Kaminski M, Rosen LS, Gordon D et al (2005) Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications [poster]. Presented at primary therapy of early breast cancer 9th international conference; 26-29 January, 2005; St. Gallen, Switzerland. Abstract 107
18. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387 (Pubitemid 33759002)
19. Rosen LS, Gordon DH, Dugan W Jr. et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43 (Pubitemid 37553537)
20. Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data. Wiley, New York, NY
21. Lawless JF (2003) Statistical models and methods for lifetime data. Wiley, Hoboken, NJ
22. Barton MB, Dawson R, Jacob S et al (2001) Palliative radiotherapy of bone metastases: An evaluation of outcome measures. J Eval Clin Pract 7:47-64 (Pubitemid 32162578)
23. Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057 (Pubitemid 46606220)
24. Coleman RE, Brown J, Cook R (2008) Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: multivariate analysis in women with metastatic breast cancer (BC). Cancer Treat Rev 34(Suppl 1):28-29 Abstract P61
25. Jackson RD, Donepudi S, Mysiw WJ (2008) Epidemiology of fracture risk in the women's health initiative. Curr Osteoporos Rep 6:155-161
26. Rosen LS, Gordon D, Kaminski M et al (2003) Long-Term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744 (Pubitemid 37238631)
27. Lipton A, Cook RJ, Major P et al (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12:1035-1043 (Pubitemid 350007015)